X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2578) 2578
Publication (208) 208
Book Review (63) 63
Newsletter (63) 63
Newspaper Article (33) 33
Magazine Article (14) 14
Book Chapter (7) 7
Conference Proceeding (2) 2
Trade Publication Article (2) 2
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (2188) 2188
humans (2024) 2024
index medicus (1779) 1779
female (1301) 1301
male (1247) 1247
infliximab (1160) 1160
middle aged (1034) 1034
adult (1005) 1005
tumor necrosis factor-alpha - antagonists & inhibitors (900) 900
rheumatology (736) 736
treatment outcome (707) 707
etanercept (670) 670
rheumatoid arthritis (635) 635
arthritis, rheumatoid - drug therapy (605) 605
antibodies, monoclonal - therapeutic use (596) 596
antirheumatic agents - therapeutic use (548) 548
aged (500) 500
therapy (472) 472
antibodies, monoclonal, humanized (440) 440
rheumatoid-arthritis (421) 421
antibodies, monoclonal, humanized - therapeutic use (418) 418
dermatology (403) 403
psoriasis (389) 389
adalimumab - therapeutic use (384) 384
arthritis (366) 366
care and treatment (360) 360
gastroenterology & hepatology (356) 356
tumor necrosis factor (342) 342
drug therapy (319) 319
severity of illness index (316) 316
efficacy (314) 314
methotrexate (309) 309
young adult (306) 306
crohns-disease (305) 305
anti-inflammatory agents - therapeutic use (303) 303
tumor necrosis factor-tnf (300) 300
pharmacology & pharmacy (288) 288
double-blind (284) 284
medicine & public health (278) 278
monoclonal antibodies (276) 276
immunology (271) 271
crohn's disease (262) 262
inflammatory-bowel-disease (253) 253
crohn disease - drug therapy (252) 252
inflammatory bowel disease (246) 246
safety (245) 245
psoriasis - drug therapy (244) 244
antibodies, monoclonal - adverse effects (238) 238
patients (234) 234
analysis (230) 230
antirheumatic agents - adverse effects (229) 229
immunoglobulin g - therapeutic use (227) 227
receptors, tumor necrosis factor - therapeutic use (225) 225
rheumatoid factor (219) 219
disease (211) 211
inflammation (211) 211
prospective studies (211) 211
retrospective studies (211) 211
adolescent (210) 210
ulcerative colitis (210) 210
antibodies (206) 206
research (205) 205
drug therapy, combination (184) 184
infliximab - therapeutic use (182) 182
health aspects (178) 178
immunogenicity (177) 177
abridged index medicus (175) 175
arthritis, rheumatoid - blood (175) 175
antibodies, monoclonal, humanized - adverse effects (169) 169
arthritis, rheumatoid - immunology (164) 164
internal medicine (164) 164
monoclonal-antibody (164) 164
cytokines (160) 160
follow-up studies (159) 159
risk factors (159) 159
time factors (159) 159
tumor necrosis factor-alpha - immunology (158) 158
tumor-necrosis-factor (157) 157
adalimumab - adverse effects (156) 156
animals (152) 152
necrosis-factor-alpha (152) 152
medical research (148) 148
inflammatory bowel diseases - drug therapy (146) 146
methotrexate - therapeutic use (146) 146
dosage and administration (145) 145
remission (143) 143
immunosuppressive agents - therapeutic use (142) 142
clinical trials (135) 135
tnf inhibitors (135) 135
tnf-alpha (135) 135
biomarkers - blood (132) 132
tumors (131) 131
medicine, experimental (129) 129
studies (128) 128
certolizumab pegol (127) 127
clinical-response (126) 126
antirheumatic agents - administration & dosage (123) 123
tumor necrosis factor-α (122) 122
musculoskeletal diseases (120) 120
adalimumab - administration & dosage (119) 119
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2654) 2654
German (11) 11
Japanese (6) 6
Russian (6) 6
Spanish (6) 6
French (4) 4
Italian (4) 4
Hungarian (3) 3
Korean (3) 3
Portuguese (2) 2
Dutch (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Nakase, H and Motoya, S and Matsumoto, T and Watanabe, K and Hisamatsu, T and Yoshimura, N and Ishida, T and Kato, S and Nakagawa, T and Esaki, M and Nagahori, M and Matsui, T and Naito, Y and Kanai, T and Suzuki, Y and Nojima, M and Watanabe, M and Hibi, T and Andoh, Akira and Ashida, Toshifumi and Endo, Katsuya and Endo, Yutaka and Esaki, Motohiro and Fujita, Hiroshi and Fujiya, Mikihiro and Haruma, Ken and Hibi, Toshifumi and Hiraoka, Sakiko and Hirata, Ichiro and Hisamatsu, Tadakazu and Honda, Yutaka and Iijima, Hideki and Iizuka, Bunei and Ikeya, Kentaro and Inoue, Takuya and Inoue, Shuji and Ishida, Tetsuya and Ishiguro, Yo and Ishihara, Shunji and Ito, Hiroaki and Iwakiri, Ryuichi and Kagaya, Takashi and Kanai, Takanori and Kashida, Hiroshi and Kato, Shingo and Kato, Jun and Katsurada, Takehiko and Kinjyo, Fukunori and Kobayashi, Kiyonori and Kodama, Mayumi and Kunisaki, Reiko and Kurahara, Koichi and Kurokami, Takafumi and Kyouwon, Lee and Matsuda, Koichiro and Matsueda, Kazuhiro and Matsui, Toshiyuki and Matsumoto, Takayuki and Mitsuyama, Keiichi and Mizokami, Yuji and Motoya, Satoshi and Naito, Yuji and Nakagawa, Tomoo and Nakamura, Shiro and Nakase, Hiroshi and Nojima, Masanori and Nomura, Masafumi and Ogawa, Atsuhiro and Okazaki, Kazuichi and Otsuka, Kazuaki and Sakuraba, Hirotake and Saruta, Masayuki and Sasaki, Makoto and Shirai, Takayuki and Suga, Tomoaki and Sugimura, Kazuhito and Sugiyama, Toshiro and Suzuki, Yasuo and Takeshima, Fuminao and Tamaki, Hiroyuki and Tanaka, Shinji and Tanida, Satoshi and Tominaga, Keiichi and Tomizawa, Taku and Watanabe, Kenji and Watanabe, Mamoru and Yamamoto, Shojiro and Yamashita, Masaki and Yoshida, Atsushi and Yoshimura, Naoki and DIAMOND Study Grp and DIAMOND study group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2017, Volume 46, Issue 9, pp. 873 - 882
Summary Background Significance of monitoring adalimumab trough levels and anti‐adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD)... 
RHEUMATOID-ARTHRITIS | MAINTENANCE | INFLAMMATORY-BOWEL-DISEASE | 6-THIOGUANINE NUCLEOTIDE | IMMUNOMODULATORS | COMBINATION THERAPY | ULCERATIVE-COLITIS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Guanine Nucleotides - blood | Adalimumab - immunology | Thionucleotides - blood | Humans | Anti-Inflammatory Agents - immunology | Male | Treatment Outcome | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - therapeutic use | Mercaptopurine - therapeutic use | Adalimumab - blood | Crohn Disease - blood | Crohn Disease - drug therapy | Sensitivity and Specificity | Adalimumab - pharmacokinetics | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Antibodies - blood | Female | Drug Therapy, Combination | Mercaptopurine - analogs & derivatives | Measurement | Viral antibodies | Medical research | Analysis | Medicine, Experimental | Antibodies | Biopharmaceutics | Blood cells | Body weight | Erythrocytes | Diamonds | Crohn's disease | Pharmacology | Regression analysis | Thioguanine | Patients | Crohns disease | Sensitivity | Regression models | Red blood cells | Multiple regression models | Predictions | Monoclonal antibodies | Remission | Pharmacokinetics | Original | Personalised Adalimumab Pharmacokinetics
Journal Article
Journal Article
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 03/2016, Volume 28, Issue 3, pp. 271 - 276
INTRODUCTIONOptimal trough levels of the anti-tumour necrosis factor agents, infliximab and adalimumab, are correlated with clinical remission. Obesity... 
Inflammatory bowel disease | Infliximab | Crohn's disease | Adalimumab | BMI | Smoking | Ulcerative colitis | NUCLEOTIDE LEVELS | CROHNS-DISEASE | SERUM INFLIXIMAB | infliximab | inflammatory bowel disease | adalimumab | PROSPECTIVE COHORT | OBESITY | INFLAMMATORY-BOWEL-DISEASE | PHARMACOKINETICS | smoking | BODY-MASS INDEX | ulcerative colitis | TNF MONOCLONAL-ANTIBODIES | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | Prospective Studies | Infliximab - analysis | Humans | Middle Aged | Anti-Inflammatory Agents - immunology | England | Male | Colitis, Ulcerative - immunology | Obesity - blood | Infliximab - pharmacokinetics | Young Adult | C-Reactive Protein - metabolism | Adalimumab - blood | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Obesity - diagnosis | Colitis, Ulcerative - drug therapy | Infliximab - blood | Body Mass Index | Cross-Sectional Studies | Inflammation Mediators - blood | Obesity - physiopathology | Biomarkers - blood | Colitis, Ulcerative - blood | Infliximab - immunology | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - administration & dosage | Colitis, Ulcerative - diagnosis | Crohn Disease - blood | Crohn Disease - drug therapy | Antibodies - blood | Drug Monitoring | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Talanta, ISSN 0039-9140, 02/2020, Volume 208, p. 120411
The detection of anti-TNF-α drugs require rapid, selective and sensitive biosensors that can be easily utilised at the point of care. Herein, we demonstrate a... 
Disulfide bond structure | Therapeutic drug monitoring | SERS nanosensor | Adalimumab | TNF-Functionalised nanomaterial | CHEMISTRY, ANALYTICAL | ENHANCED RAMAN-SCATTERING | TNF-Functlonalised nanomaterial | NANOPARTICLES | MICROCYSTIN | SERS | AMINO-ACIDS | DISEASE | ADALIMUMAB ANTIBODIES
Journal Article
Frontiers in immunology, ISSN 1664-3224, 2018, Volume 9, p. 2865
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, p. e0167757
TNF-alpha has a central role in the development and maintenance of psoriatic plaques, and its serum levels correlate with disease activity. Anti-TNF-alpha... 
RHEUMATOID-ARTHRITIS | THERAPY | DENDRITIC CELLS | MULTIDISCIPLINARY SCIENCES | PHASE-III | DISEASE | NECROSIS-FACTOR-ALPHA | RANDOMIZED CONTROLLED-TRIAL | INFLIXIMAB | ETANERCEPT | GENE POLYMORPHISMS | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Anti-Inflammatory Agents - immunology | Male | Dermatologic Agents - therapeutic use | Monocytes - immunology | Infliximab - therapeutic use | Leukocytes, Mononuclear - immunology | Receptors, Tumor Necrosis Factor - blood | Tumor Necrosis Factor-alpha - immunology | Anti-Inflammatory Agents - therapeutic use | Antibodies - immunology | Adult | Female | Psoriasis - blood | Psoriasis - immunology | Adalimumab - immunology | Leukocytes, Mononuclear - drug effects | Psoriasis - drug therapy | Infliximab - immunology | Monocytes - drug effects | Adalimumab - therapeutic use | Etanercept - immunology | Antibodies - blood | Aged | Dermatologic Agents - immunology | Receptors, Tumor Necrosis Factor - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Cohort Studies | Etanercept - therapeutic use | Drugs | Pathogenesis | Antibodies | Amino acids | Leukocytes (mononuclear) | Systematic review | Cell adhesion & migration | Receptors | Etanercept | Infliximab | Lymphocytes | Surgery | Modulation | Peripheral blood mononuclear cells | Tumor necrosis factor-TNF | Life sciences | Drug dosages | Plaques | Immunoglobulins | Psoriasis | Cytokines | Dendritic cells | Dermatology | Inflammation | Dentistry | Tumor necrosis factor-α | Patients | Medicine | Serum levels | Monocytes | Rheumatoid arthritis | Morphology | Monoclonal antibodies | TNF inhibitors | Plasma levels
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 09/2017, Volume 153, Issue 3, pp. 835 - 857.e6
Therapeutic drug monitoring (TDM), which involves measurement of drug or active metabolite levels and anti-drug antibodies, is a promising strategy that can be... 
CRP | RCT | 6-MP | C-reactive protein | TPMT | CBC | IBD | TNF | 6-methylmercaptopurine | 6-MMP | ulcerative colitis | AGA | TDM | therapeutic drug monitoring | AZA | azathioprine | 6-TGN | Crohn's disease | homogenous mobility shift assay | RIA | ECLIA | Grading of Recommendations Assessment, Development, and Evaluation | inflammatory bowel disease | relative risk | 6-thioguanine | complete blood count | randomized controlled trial | anti-drug antibody | thiopurine methyltransferase | HMSA | electrochemiluminescence immunoassay | radioimmunoassay | 6-mercaptopurine | tumor necrosis factor | enzyme-linked immunosorbent assay | GRADE | ADAb | confidence interval | American Gastroenterological Association | ELISA | IMPROVE OUTCOMES | ADALIMUMAB TROUGH LEVELS | THIOPURINE S-METHYLTRANSFERASE | CROHNS-DISEASE | AZATHIOPRINE THERAPY | ULCERATIVE-COLITIS | PEDIATRIC-PATIENTS | 6-THIOGUANINE NUCLEOTIDE LEVELS | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | INDUCTION INFLIXIMAB LEVELS | Inflammatory Bowel Diseases - drug therapy | Body Weight | Azathioprine - pharmacokinetics | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Drug Monitoring - methods | Azathioprine - blood | Methyltransferases - blood | Antibodies, Monoclonal - blood | Immunosuppressive Agents - blood | Thionucleosides - therapeutic use | Thionucleosides - pharmacokinetics | Thionucleosides - blood | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Continuing medical education | Biological products | Health aspects | Gastrointestinal diseases
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 05/2016, Volume 22, Issue 8, pp. 1999 - 2015
Background:Biological tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory bowel disease and redefined treatment goals to... 
certolizumab pegol | TNF inhibitor | infliximab | Crohn's disease | adalimumab | golimumab | inflammatory bowel disease | antibodies | pharmacodynamic | ulcerative colitis | pharmacokinetic | loss of response | therapeutic drug monitoring | personalized therapy | NECROSIS-FACTOR ANTAGONISTS | INFLIXIMAB TREATMENT FAILURE | REGULATORY T-CELLS | QUALITY-OF-LIFE | POST-HOC ANALYSIS | LONG-TERM EFFICACY | C-REACTIVE PROTEIN | CROHNS-DISEASE | RHEUMATOID-ARTHRITIS PATIENTS | MANAGING SECONDARY LOSS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Antibodies, Monoclonal - blood | Immunosuppressive Agents - blood | Adalimumab - blood | Treatment Failure | Adalimumab - pharmacokinetics | Certolizumab Pegol - pharmacokinetics | Certolizumab Pegol - therapeutic use | Infliximab - blood | Antibodies, Monoclonal - immunology | Certolizumab Pegol - blood | Certolizumab Pegol - immunology | Inflammatory Bowel Diseases - drug therapy | Adalimumab - immunology | Antibodies, Monoclonal - pharmacokinetics | Infliximab - immunology | Adalimumab - therapeutic use | Immunosuppressive Agents - immunology | Antibodies - blood | Drug Monitoring | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article